Sort
51,593 grants matching “hepatitis”
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
$638,567Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2013 · CA
NONINJECTING HEROIN USERS, NEW INJECTORS AND HIV RISK
$638,486National Development &Res Institutes · R01 · FY2000 · DA
HIV-1 Preintegration Trafficking and Nuclear Localization
$638,417Alan N. Engelman · Dana-Farber Cancer Inst · R01 · FY2022 · AI
Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseases
$638,405Alexander Revzin · Mayo Clinic Rochester · R01 · FY2025 · DK
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
$638,384Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Molecular basis of altered drug metabolism during pregnancy
$638,285Hyunyoung Jeong · University Of Illinois At Chicago · R01 · FY2018 · HD
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLD
$638,277David E Cohen · Brigham And Women'S Hospital · R01 · FY2015 · DK
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond
$638,187Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · AI
Project 2: Durable impact of HCV on innate and adaptive immunity
$638,169Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2024 · AI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants
$637,960Marianna K Baum · Florida International University · R01 · FY2011 · DA
Drug eluting injectable biomaterials for next generation chemoembolization
$637,881Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2023 · CA
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors
$637,836John E Tavis · Saint Louis University · R01 · FY2023 · AI
NONINJECTING HEROIN USERS, NEW INJECTORS AND HIV RISK
$637,814National Development &Res Institutes · R01 · FY2001 · DA
Glycemic Load and Resistance Training on Endothelial Function and Inflammation
$637,782Catherine L Carpenter · University Of California Los Angeles · R01 · FY2014 · DK
Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases
$637,742Patrizia Farci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
HIV Risks and Transitions to Injection among Non-IDUs
$637,741Universidad Central Del Caribe · R01 · FY2002 · DA
Vitamin A metabolism in the adult lung
$637,716Igor Shmarakov · Rutgers, The State Univ Of N.J. · R01 · FY2025 · HL
Investigation of management and disease manifestations of viral hepatitis
$637,647Theo Heller · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK
Investigation of non-cirrhotic portal hypertension.
$637,647Theo Heller · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK
Conserved Fetal Epigenomic and Metagenomic Signatures in a Primate Model of Maternal Obesity
$637,564Kjersti Marie Aagaard-Tillery · Baylor College Of Medicine · R01 · FY2021 · DK
Genetic basis of virus induced Biliary Atresia
$637,505Gregory M Tiao · Cincinnati Childrens Hosp Med Ctr · R01 · FY2025 · DK
When pandemics collide: The intersection of the opioid crisis, COVID-19 and HIV pandemics among people who inject drugs in the United States
$637,354Becky Lynn Genberg · Johns Hopkins University · R01 · FY2021 · DA
Implementation Research for Vulnerable Women in South Africa
$637,352Wendee M Wechsberg · Research Triangle Institute · R01 · FY2017 · AA
Hepatotoxic effects of perfluoroalkyl substances: a new epidemiological approach for studying environmental fatty liver disease
$637,351Vaia Lida Chatzi · University Of Southern California · R01 · FY2020 · ES
Refanalin for Liver Transplantation
$637,350Angion Biomedica Corporation · R44 · FY2005 · AA